CHTF18 Antibody (C-term) Blocking Peptides
- Known as:
- CHTF18 Antibody (C-terminus) Blocking Peptides
- Catalog number:
- BP12986b
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- CHTF18 Antibody (C-term) Blocking Peptides
Related genes to: CHTF18 Antibody (C-term) Blocking Peptides
- Gene:
- CHTF18 NIH gene
- Name:
- chromosome transmission fidelity factor 18
- Previous symbol:
- C16orf41
- Synonyms:
- CHL12, C321D2.4, Ctf18
- Chromosome:
- 16p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-04
- Date modifiied:
- 2015-06-19
Related products to: CHTF18 Antibody (C-term) Blocking Peptides
Related articles to: CHTF18 Antibody (C-term) Blocking Peptides
- The use of PARP inhibitors (PARPi) has profoundly changed the treatment of BRCA1/BRCA2-mutated cancers. Despite this, acquired resistance to PARPi has become a major challenge in the clinic. Hence, a more detailed understanding of the mechanisms underlying PARPi sensitivity is crucially needed. Here, we show that loss of the alternative clamp loader complex CHTF18-RFC2/5 leads to a remarkable sensitization to PARPi. Loss of CHTF18 is not associated with defective RAD51 foci formation excluding a defect in homologous recombination. On the contrary, treatment with PARPi triggers replicative gap accumulation in CHTF18 knockout (KO) cells. By performing transient silencing experiments, we highlight PARP1-PARP2 trapping at replicative gaps as a major determinant of sensitivity to these compounds. Crucially, loss of 53BP1 does not rescue PARPi sensitivity in CHTF18 KO cells, outlining Polε and the CHTF18-RFC2/5 complex as potential novel targets for cancer therapeutics. - Source: PubMed
Publication date: 2026/06/03
Buckley-Benbow LaurynOzgencil MeryemTardocchi AlessiaAgnarelli AlessandroBellelli Roberto - Cryptozoospermia is defined, according to WHO criteria, as the absence of spermatozoa in fresh semen preparations but the presence of rare spe matozoa after centrifugation. Identifying candidate genes and their clinical phenotypes is essential for understanding its etiology and developing targeted therapies. - Source: PubMed
Publication date: 2026/06/04
Hu YenaPi YuzeMeng LanlanTang BinHe YutongZhang HuanTu ChaofengTan YueqiuHu Liang - Laryngeal cancer (LC) is a common malignant tumor. Telomere-related genes (T-RGs) play critical roles in cellular senescence and carcinogenesis, but their prognostic relevance in LC remains to be fully elucidated. Therefore, exploring the prognostic genes related to telomeres in LC is important. - Source: PubMed
Publication date: 2026/04/08
Cheng YesongZhao YingjieHe LinHuang DingqiangZhao FeipengShi XiangyangTang WensongLiu YiZou WujunTang XiaolongHe Yi - Approximately 30% to 40% of patients with Diffuse Large B-cell Lymphoma (DLBCL) experience treatment failure, whereas the current International Prognostic Index (IPI) fails to adequately reflect the intrinsic biological features. This study aimed to investigate the prognostic value of Replication Factor C genes (RFCs) in DLBCL and construct a prognostic risk model. Three DLBCL datasets were downloaded from the Gene Expression Omnibus (GEO) database (GSE181063, GSE10846, GSE31312). Multivariate Cox proportional hazards regression analysis identified high expression of RFC2 and RFC4 as independent adverse prognostic factors (RFC2: HR = 1.46, P = 0.037; RFC4: HR = 1.36, P = 0.034), which were significantly associated with age ≥ 60 years, elevated lactate dehydrogenase (LDH) levels, and poor Eastern Cooperative Oncology Group (ECOG) performance status. Mechanistically, the RFC2 high-expression group exhibited a significant increase in tumor mutational burden (TMB). Protein-protein interaction (PPI) analysis revealed that RFC2 and RFC4 interact with CHTF18, PCNA, and other proteins to maintain genomic stability. Gene set enrichment analysis (GSEA) indicated that RFC2 and RFC4 high-expression groups were enriched in the DNA replication and DNA damage repair (DDR) pathways. Competing endogenous RNA (ceRNA) network analysis predicted miR-34a-5p as an upstream regulator; PARD6G-AS1, TERC, and LINC00662 upregulating RFC2 and RFC4 by sponging miR-34a-5p. The RFC-based prognostic model significantly stratified high- and low-risk patients, with superior predictive performance compared to the IPI score. Validation in our clinical cohort confirmed that the high-risk group had significantly shorter overall survival (OS) (P = 0.003). This study provides a novel tool for individualized prognostic assessment in DLBCL and suggests RFC2 and RFC4 as potential therapeutic targets. - Source: PubMed
Publication date: 2026/04/04
Wang ShuainanLiu YangZang HaoyuGuo LaibingDu WenjingSong JingyanWang FeiLu LuoLi QingShi YongqiangChen TongbingGu Weiying - The objective of this study was to identify key idiopathic pulmonary fibrosis (IPF) related genes, thereby establishing a novel IPF diagnostic/warning panel and proposing drugs against IPF based on the strategy of targeting key genes. - Source: PubMed
Publication date: 2026/01/15
Song YuMeng XianglinTian JiaqiHao YunheZeng KaiZhang LikunZhang JiannanZhang KailiXin YuWang ChangsongYu Kaijiang